Novel influenza vaccine : Calixar patent granted in Europe

October 15, 2019

This patent issued from the fruitful collaboration with the academic laboratory VirPath is a great step forward in the generation of safer and more efficient vaccine candidates.

For licensing opportunities, contact us here

Share this post

Secure and boost
your discovery programs

Starting from native material or recombinant systems, we succeed with all types of proteins: Kinases, Phosphatases, Ubiquitins, Epigenetic Proteins, GPCRs, Ion Channels, Transporters, Receptors and Viral Proteins.